The anti-tumor efficacy of adoptively transferred T cells requires their in vivo persistence and memory polarization. It is unknown if human chimeric antigen receptor (CAR)-expressing T cells can also undergo memory polarization. We examined the functional status of CAR CD8 + CM and EM T cells in that CD27, but not CD28, was downregulated. In addition, CD8
+ LeY-T cells expressed high levels of perforin, similar to starting CD8 + Eff. CD8 + LeY-T cells also showed hallmarks of both memory and Eff function, underwent homeostatic proliferation in response to interleukin (IL)-15, and showed interferon (IFN)-g production and cytotoxicity in response to Le-Y antigen on OVCAR-3 (human ovarian adenocarcinoma) cells. This study confirms CD8 + LeY-T cells have a CM-and EM-like phenotype and heterogeneous
Introduction
Adoptive transfer of T cells has shown promise as a form of immunotherapy to treat established tumors in patients. [1] [2] [3] Efficacy in animal models [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] has now been translated into clinical trials using either ex vivo expanded tumor-infiltrating lymphocytes [16] [17] [18] or genemodified T cells [19] [20] [21] [22] to treat tumors. Persistence of adoptive chimeric antigen receptor (CAR) T cells is associated with tumor regression; 17, 18, 22 furthermore, animal studies suggest that persistence of adoptive T cells and a protective immune response is associated with the ability of adoptive T cells to form memory 11, 23, 24 after contact with cognate antigen or in response to homeostatic cytokines. 25 Human CD8
+ antigen-specific T cells can be grouped into functional subsets using tetramer staining and a multi-parameter phenotype. 
/CD28
À /perforin hi ) cells. 26 Other features have been used to define the functional status of human CD8 + T cells including proliferation in response to cognate antigen or homeostatic cytokines, and the cytokine secretion profile. 27, 28 Eff CD8 + T cells secrete high levels of interferon (IFN)-g in response to peptide and have a low proliferative response to either T-cell antigen receptor signal or interleukin (IL)-15. 27, 28 In contrast, CM CD8 + T cells secrete IL-2 and proliferate in response to antigen or IL-15. 27, 28 The in vivo behavior of these T-cell subsets and the correlation with anti-tumor efficacy has, to date, largely been examined in mouse models. 11, 23, 24 When antigen-specific T cells at different functional states were adoptively transferred into tumorbearing animals, the T cells with a less mature functional status (that is, pre-Eff) persisted in vivo and had improved anti-tumor efficacy. 11 In contrast, differentiated Eff cells with higher in vitro cytolytic capacity had poorer anti-tumor efficacy and persistence after adoptive transfer. 11 Clinical studies of ex vivo-expanded and adoptively transferred human tumor-infiltrating lymphocytes) have shown that in vivo persistence is associated with melanoma regression. 17, 18 Furthermore, detailed analysis of the persistent melanoma-specific T-cell clones have shown that persistence of T-cell clones after adoptive transfer was associated with long telomeres, and that the cells had acquired their functional phenotype in vivo. 17 Muul et al. 34 showed that gene-modified cells, expressing the adenosine deaminase gene, can persist in vivo up to 12 years. However, until recently, equivalent data for CAR T cells have been absent. Barber et al. 29 recently described CD8 + T cells expressing a chimeric NKG2D receptor after a short-term transduction and expansion culture. At the end of transduction culture, the chimeric NKG2D T cells had cytolytic function against human myeloma cell lines, and secreted IFN-g, granulocytemacrophage colony-stimulating factor, tumor necrosis factor (TNF)-a and CCL5 after co-culture with myeloma cell lines. Furthermore, the chimeric NKG2D T cells expressed early differentiation markers, including CD27, CCR7 and CD62L. 29 In addition, Till et al. 30 described the phenotype of chimeric receptor-expressing CD8 + T cells directed to CD20. These cells were produced after a lengthy re-stimulation protocol and were largely Eff cells
. We have developed an ex vivo transduction and expansion protocol using a novel retroviral construct 31 to produce CAR T cells for adoptive immunotherapy. The cells express a chimeric protein comprising an extracellular scFv directed to the Lewis Y antigen (LeY), a transmembrane CD8 domain and intracellular CD28 and CD3z signaling domains (LeY-T). These T cells caused established LeY-expressing tumors to regress in a xenotransplantation model 31 while in vitro studies showed the LeY-T cells induced lysis of LeY-expressing tumor targets, of both epithelial and hematological origin. 31 Our recent studies have shown the LeY antigen is expressed by a subset of patients with multiple myeloma (MM) or acute myeloid leukemia (Peinert et al. unpublished data). In this study, we have performed a comprehensive analysis of the CAR anti-LeY-T cells, and confirmed the cellular content of the product as activated CD8 + and CD4 + T cells. The CD8 + LeY-T cells have both a CM and EM phenotype and a heterogeneous functional state shown by proliferation in response to IL-15 or engagement of LeY antigen on a tumor cell. The CD8 + LeY-T cells also secrete high levels of IFN-g and kill LeY antigen-expressing tumor cells. This data suggest the LeY-T ex vivo transduction and expansion protocol will generate CAR T cells capable of persisting in vivo and providing anti-tumor responses after adoptive transfer into patients to treat MM or acute myeloid leukemia.
Results
The T-cell transduction and expansion culture system expands activated CD8 + T cells
We have designed a T-cell transduction and expansion technique, incorporating a novel retroviral construct, to produce autologous gene-modified T cells for adoptive therapy of tumors expressing the LeY. In the first part of this study, T cells were harvested at culture days 0, 3 and 10 to examine the relative frequency of T-cell subsets (including CD4 + and CD8 + subsets), B and NK cells. We observed a consistent and statistically significant decrease in B cell and NK cell frequencies and a concomitant increase in CD8 + and CD4 + T cells over the 10-day expansion culture (Figure 1 and Supplementary  Figure 1 ). This trend in lymphocyte subset changes throughout the LeY-T culture period was consistent between donors. Thus, when all normal transduction (n ¼ 14) cultures were analyzed, a statistical difference (Po0.05) was found between days 0 and 10 frequency of CD3 (total T), CD8 + T cell, B cell (CD19) and NK cells (CD3À/CD16 and CD56 + ) Further analysis of the LeY-T cells showed there was dramatic upregulation of the activation markers CD25 (ILRa) and CD69 on both CD4 + and CD8 + T cells on days 3 and 10 of culture (data not shown). By day 10, the CD8+ T cells had lost CD69 expression, but still retained CD25 (ILRa) at moderate levels on the cell surface.
Subsequently, we examined the expression of chimeric protein on transduced T cells ( Table 1 ). In addition, a regression analysis was performed (using the data from Supplementary Table 1 + Eff T cells, CD27 is absent from the majority of cells. CD28 expression on circulating CD8 + T cells is uniform from N through to EM differentiation, however, like CD27 it is downregulated on CD8 + Eff T cells. In contrast, day 10 CD8 + LeY-T cells retained CD28, but lost CD27 expression at a much higher level than observed on circulating CD8 + CM and EM T cells.
Ex vivo expanded LeY-T cells express IL-2/15Rb, not IL-7Ra, and proliferate in response to IL-15
Previous studies have shown that IL-15, rather than IL-7 or IL-2, is more important for homeostatic proliferation of memory CD8 + T cells. 32 Therefore, we examined CD8 Subsequently, proliferation of day 10 CD8 + LeY-T cells was examined in vitro in the presence of the homeostatic cytokines IL-2, IL-15, IL-7 or IL7 plus IL-15. CD8 + T-cell proliferation in response to IL-2 or IL-15 was substantially higher than that observed in response to IL-7 ( Figure 5 ). Furthermore, carboxyfluorescein succinimidyl ester (CFSE) proliferation curves indicated that division index, proliferation index and % cells undergoing cell division were all significantly higher for CD8 + T cells cultured in IL-15 versus IL-7 ( Figure 5 ). There was no statistical difference in CD8 + LeY-T-cell proliferation in response to IL-7 plus IL-15 versus IL-15 alone (data not shown). In addition, viability of CD8+ T cells at the end of the CFSE proliferation was assessed. Thus, CD8+ T-cell viability (for four normal donors, mean ± s.e.m.) was 45±4.5% in IL-7, 64±6.4% in IL-2 and 71±7.1% in IL-15. CD8+ T-cell viability was significantly higher in either IL-2 versus IL-7 (P ¼ 0.020) or IL-15 versus IL-7 (P ¼ 0.028).
Contact with LeY antigen on tumor cells induces CD8 + T-cell proliferation, IFN-c secretion and tumor cell lysis
Rapid proliferation in response to cognate antigen is a hallmark of CD8 + T-cell memory. 28, 32 To examine the proliferative capacity of the LeY-T cells in response to LeY antigen, empty vector control or LeY-T cells were cocultured with the Le-Y-expressing cell line OVCAR-3 (human ovarian adenocarcinoma) for 5 days. This study was performed in the absence of exogenous cytokines to reveal the proliferative capacity of LeY-T cells in response to cognate antigen alone, as might be the case in vivo in the potentially immunosuppressive environment of a tumor. The LeY-T cells proliferated rapidly in response to OVCAR-3, irrespective of the presence or absence of major histocompatibility complex class I and II blocking antibodies (Figures 6a and b) . In contrast, there was no proliferation of empty vector control T cells co-cultured with OVCAR-3 (Figures 6c and d) . Furthermore, day 10 CD8 + LeY-T cells downregulated CD45RA and CD27 on dividing cells after contact with LeY antigen-expressing OVCAR-3 cells (Supplementary Figure 3) ; blocking antibodies to major histocompatibility complex class I and II did not inhibit proliferation nor loss of CD45RA Figure 4) secreted IFN-g. In addition, plate-bound OKT3-induced IL-4 secretion by CD8-negative LeY-T (5.6% in Figure 7b ) and control T cells (9.1% in Supplementary  Figure 4) . Importantly, when challenged by tumor cells, the CD8+ LeY-T-cell response was shown to be specific. Thus, CD8
+ LeY-T cells secreted IFN-g (1.71%) but no Figure 4) secreted IL-4 constitutively or in the presence of tumor cells. Finally, the ability of the day 10 LeY T cells to lyse LeYexpressing tumor targets was assessed in a standard Cr-release assay using OVCAR-3 as the tumor target (Figure 7c) . These results have shown that OVCAR-3 lysis occurred over a range of Eff:target ratios by LeY T cells and not control vector T cells (Figure 7c ). This data showed that lysis by transduced T cells was antigen specific.
Discussion
Recent innovations in adoptive T-cell immunotherapy include re-directing T-cell recognition to the tumor cell by modifying the T-cell genome using retroviral transduction. 33 We have previously shown that transduced T cells (LeY-T) can reject LeY antigen-expressing tumors. 31 This same technique is to be used by our group to generate autologous LeY-T cells for use in a clinical trial of adoptive T-cell immunotherapy in MM and acute myeloid leukemia. As part of our development of this clinical trial strategy, we extensively analyzed our post-expansion CAR T-cell product in both normal donor and patients with active MM to determine the potential for LeY-T cells to form memory and persist after adoptive transfer. In our analysis, we showed a dramatic change in cell subtypes over the transduction culture period. By day 10, the culture comprised activated T cells, with a higher frequency of CD8 + rather than CD4 + T cells, a consistent finding between donors. Both transduced CD4 + and CD8 + T cells expressed the chimeric receptor and the chimeric receptor expression level correlated with mean genomic DNA LeY Tg copy number. In this study, 425% of CD4 + T cells in the transduction and expansion culture (from both the normal donors and MM patients) expressed the chimeric receptor, which suggests the transduction is generating sufficient CD4 + T-cell help for optimal anti-tumor response. 7 Information from two sources instigated this study. First, previous studies have examined the potential for gene-modified cells to persist in patients; in one notable example, 34 adenosine deaminase-expressing lymphocytes were identified 12 years after adenosine deaminase gene therapy for two patients. The patients' circulating T cells contained the adenosine deaminase vector in 20% and o0.1% of cells respectively; 34 this disparity was likely due to an immune response by the second patient to the gene transfer system. In the second study, Chimeric antigen receptor CD8 + T cells have a memory phenotype P Neeson et al autologous T cells were transduced to express a melanoma antigen-specific T-cell receptor and then adoptively transferred into patients to treat pre-existing melanoma. The two patients who had objective tumor regressions had persistence of circulating gene-modified T cells. 22 To determine the potential for LeY-T cells to form memory and persist after adoptive transfer, we examined the functional status of the CD8 + LeY-T cells throughout the transduction and expansion culture. Phenotype studies at day 0 showed CD8 + T cells comprised N, CM, EM and Eff functional subsets. By the end of the transduction culture, the CD8 + LeY-T cells 30 produced CD8 + T cells that were more differentiated and largely Eff (CD62LÀ/CCR7À/ CD45RAÀ/CD127À) cells. Although the T-cell activation step (OKT3 plus IL-2 for 3 days) was the same for all three studies, in the Barber et al. 29 and our study the T cells were subsequently retrovirally transduced and expanded in IL-2 for 5 or 7 days, respectively. In contrast, Till et al.
30 transfected activated T cells and then generated T-cell clones by limiting dilution and expanded through eight rounds of re-stimulation. The T-cell expansion protocols used by Barber et al. 29 and our study were similar and generated both memory and 'early Eff' CD8 + T-cell phenotype. In contrast, Till et al.
30
used a different production approach that produced largely Eff CD8 + T cells. The persistence of CD8 + LeY-T cells after adoptive transfer will depend on their ability to respond to T-cell homeostatic cytokines, particularly IL-15. 23 For this reason, we next examined CD8 + LeY-T-cell expression of homeostatic cytokine receptor subunits as well as their ability to proliferate in vitro in response to IL-2, IL-7 or IL-15. By the end of the transduction culture, CD8
+ LeY-T-cell expressed CD132 (gcR) and CD25 (IL2Ra), and downregulated CD127 (IL7Ra). Furthermore, CD8 + LeY-T cells proliferated in response to IL-2 or IL-15, but less in response to IL-7. Importantly, our in vitro co-culture studies showed LeY-T cells undergo rapid and specific proliferation in response to Lewis antigen on tumor cells, without the need to provide exogenous cytokine support. 
Materials and methods

Cell lines
OVCAR-3, HCT116 (human colorectal carcinoma), K562 (human erythroleukemia), RPMI8226 (human MM) and MDA-MB-435 (human breast carcinoma) cells were obtained from the ATCC (Manassas, VA, USA). All cell lines were cultured in complete RPMI1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine.
Gene-modified T-cell culture
Peter MacCallum Cancer Center human ethics approval for this study was provided for normal donor (n ¼ 14) and MM (n ¼ 6) peripheral blood. After informed consent, anti-coagulated whole blood was collected from either normal donors or patients with MM. Peripheral blood mononuclear cell were isolated by density gradient centrifugation and red cells lysed with Tris-buffered ammonium chloride buffer. Peripheral blood mononuclear cells were cultured at 1 Â 10 6 ml -1 in 60-100 ml of AIM-V media (GIBCO, Carlsbad, CA, USA) supplemented with 2% heat-inactivated human AB serum (Valley Biomedical, Winchester, VA, USA), 30 Zg ml -1 OKT3 (Ortho Biotech, Horsham, PA, USA) and 600 IU ml -1 human recombinant IL-2 (Biological Resources Branch Preclinical Repository, NCI, Frederick, MD, USA), termed T-cell medium, for 3 days at 37 1C and 5% CO 2 . Retronectin (TAKARA, Otsu, Shiga, Japan; Scientifix, Cat No: T100B)-coated culture flasks were prepared by adding retronectin at 30 mg ml -1 in phosphate-buffered saline (PBS), pH 7.4 in a 175 cm 2 flask and incubated for 2 h at room temperature. The retronectin solution was aspirated from the flask and the flask washed with 30 ml PBS, pH 7.4 (calcium and magnesium free). Retroviral supernatant (Eufets AG, Germany) from the PG13 producer cell line (Peinert et al. unpublished data) was added to retronectin-coated 175 cm 2 flasks, incubated for 4 h at 37 1C in 5% CO 2 and then at 4 1C overnight. Subsequently, activated T cells (prepared as above) were added to the retronectin-coated 175 cm 2 flask in T-cell medium (60-100 ml culture at 1 Â 10 6 cells ml -1 ). The transduction culture was incubated overnight at 37 1C in 5% CO 2 , a second round of transduction was then performed by transferring the T cells to another retronectin-coated 175 cm 2 flask for a further 24-h culture. T cells were then harvested from the second flask, counted
Chimeric antigen receptor CD8 + T cells have a memory phenotype P Neeson et al and re-seeded into 175 cm 2 flasks at 1 Â 10 6 ml -1 in T-cell medium. The T-cell medium was changed every 3 days and the cell density maintained at 1 Â 10 6 ml -1
. Cells were harvested from this transduction and expansion culture on day 10.
Antibodies
Mouse anti-human CD3-fluorescein isothiocyanate (FITC), CD3-Pacific Blue, CD4-FITC, CD4-APC, CD4-AmCyan, CD4-APCCy7, CD8-PECy7, CD8-APCCy7, CD19-PerCPCy5.5, CD16 and CD56-PE, CCR7-PECy7, CD45RA-FITC, CD27-APC, CD28-PerCPCy5.5, CD25-APC, CD69-PECy7, IL2-FITC, IL4-PE, IFN-g-APC, CD122-PE, CD127-PE, CD132-PE, IL15Ra-PE and mouse isotype controls were all from BD Biosciences (San Diego, CA, USA). In addition, mouse anti-human perforinphycoerythrin was from e-Bioscience (San Diego, CA, USA), the LeY anti-idiotype antibody (LMH-3) was a kind gift from Andrew Scott (Ludwig Institute of Cancer Research, Austin Branch, Heidelberg, Melbourne, Australia).
Phenotyping
T cells were stained by direct method (30 min at 4 1C) using the conjugated antibodies listed above. Cells were washed twice in fluorescence-activated cell sorting buffer (PBS, pH 7.4 plus 2% fetal bovine serum) before data acquisition on the BDLSRII flow cytometer using the FACSDiva software (BD Biosciences, San Diego, CA, USA). List mode files were then analyzed using the FlowJo (Trees Star Inc., Portland, OR, USA) software. For combination surface protein and cytoplasmic perforin staining, T cells were stained with conjugated antibodies by direct method (as above), cells were washed in PBS pH 7.4, fixed in 1% paraformaldehyde in PBS for 20 min on ice. T cells were then permeabilized in 0.2% saponin with an optimal concentration of phycoerythrinconjugated perforin antibody for 1 h on ice. After two wash steps in PBS pH 7.4, cells were analyzed on the fluorescence-activated cell sorting.
CFSE proliferation Homeostatic proliferation. T cells were washed twice in PBS pH 7.4 and stained with 2 mM CFSE (Invitrogen, Carlsbad, CA, USA) for 5 min. To stop the staining, equal volumes of RPMI1640 with 10% HI-AB serum (RAB10) was added and the cells washed twice in RAB10. Subsequently CFSE-stained T cells were cultured in triplicate wells for 7 days at 37 1C, 5%CO 2 in RAB10 supplemented with either 20 IU ml -1 IL-2, 10 Zg ml -1 IL-7 (Peprotech, Rocky Hill, NJ, USA), 10 Zg ml -1 IL-15 (Peprotech), or 10 Zg ml -1 IL-7 and IL-15. After 7 days, the cultured CFSE-stained T cells were stained with CD3-APC, CD4APC-Cy7, CD8-PerCPCy5.5 and LiveDead UV blue (Invitrogen) for 30 min at 4 1C. Cells were then analyzed on the BDLSRII flow cytometer (BD Biosciences) using the FACSDiva acquisition software (BD Biosciences) and analyzed by FlowJo software. CFSE histograms were gated on viable cells followed by CD3 and CD4 or CD8. The FlowJo software calculated the derived parameters including '% cells divided' (% of the original cells which divided), the 'division index' (mean number of divisions a dividing cell from the original population underwent) and the 'proliferative index' (mean number of cell divisions a dividing cell underwent). This derived data were pooled from four different donors and analyzed by non-parametric one-way analysis of variance test for statistical difference across the test groups, followed by direct comparison of paired groups using the Student's t-test.
Proliferation in response to LeY targets. OVCAR-3 cells were cultured overnight at 37 1C at 1 Â 10 6 ml -1 and then co-cultured in a 1:1 ratio with CFSE-labeled LeY-T cells. The LeY-T cells were then harvested from transduction and expansion culture on day 10. Co-cultures were maintained in RAB10 (no added cytokines) for 5 days at 37 1C in 5% CO. In addition, in some wells the major histocompatibility complex class I (clone W6/32) and major histocompatibility complex class II (clone IVA12) were added at 100 mg ml -1 to block T-cell antigen receptor recognition of allo-antigens. On day 5, cells were harvested, stained by direct method with CD8-PECy7 and CD4-APCCy7, plus the viability marker Fluorogold, and then analyzed on the BDLSRII flow cytometer (BD Biosciences) using the FACSDiva acquisition software (BD Biosciences) and analyzed by FlowJo software. CFSE histograms were gated on viable cells followed by CD4 or CD8 to determine their proliferative potential in response to antigen contact.
Cytokine secretion
Cytokine production was assessed after 24-h co-culture of the CAR-T cells with either 3.5 Â 10 6 per well Le-Y positive (K562 or RPMI8226) or negative (MDA-MB-435) cells in a 1:1 ratio. Control wells included media alone or wells pre-coated with anti-OKT3 (10 mg ml -1 ). The supernatant was collected for CBA assay and the cells retained for intracellular cytokine content assay by fluorescenceactivated cell sorting.
Intracellular cytokine secretion. Golgi plug (BD Biosciences) containing Brefelden A was added to each co-culture well (1 ml Golgi Plug ml -1 culture, cells were at 1 Â 10 6 ml -1
) for 4 h. T cells were harvested from the plate, washed once in PBS and stained with CD8-PerCPCy5.5. After washing in PBS, T cells were fixed in 1% paraformaldehyde in PBS for 20 min at room temperature, washed in PBS, permeabilized in 0.2% saponin in PBS and stained for intracellular cytokines (IL-2, IL-4, IFN-g) at 4 1C for 30 min. The stained cells were then analyzed as above by flow cytometry.
Cytokine bead array. A CBA was performed on the co-culture supernatant (harvested above) using the Th1/ Th2 CBA kit (BD Biosciences) according to the manufacturer's instructions. This kit analyses IL-2, TNF-a, IFN-g, IL-4, IL-5 and IL-10.
Cytotoxicity assay
Cytotoxicity was assessed using a standard 4-h 51 Cr-release assay. Briefly, the target cells (OVCAR-3) were loaded with 51 Cr and incubated with transduced T cells in an increasing Eff to target ratio for 4 h with specific killing measured by 51 Cr release. Empty vector T cells served as control. The percent-specific lysis 35 1 Â 10 6 cells were lysed in 400 ml lysis buffer. PCR was performed on a ABI Prism 7000 Sequence Detection System (Applied Biosystems) using TaqMan (Applied Biosystems) chemistry according to manufacturer's instructions with 10 ml DNA solution and primers LeY (forward) LeY (reverse) and am (reverse) at 300 ZM, primer am (forward) at 100 ZM and probes at 200 ZM. All samples were run in triplicate. Standard curves were prepared using serial dilutions of pSAMEN-LeY plasmid (LeY) or DNA prepared from normal peripheral blood mononuclear cells (am). The copy number of unknown samples was interpolated from the standard curves using GraphPad Prism software Inc. (La Jolla, CA, USA). The am gene was assumed to be single copy and diploid and used to estimate copy number per cell for the LeY gene.
